EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia
Rhea-AI Summary
EUDA Health Holdings (NASDAQ: EUDA) has announced an update to its previously disclosed strategic partnership with Guangdong Cell Biotech. Instead of forming a joint venture, the companies have opted for a commercial distribution arrangement through EUDA's subsidiary CK Health Plus Sdn Bhd.
On April 22, 2025, CK Health signed a collaboration agreement with Keylock, an authorized distributor of Guangdong Cell Biotech, enabling EUDA to market and sell stem cell therapies to customers in Singapore and Malaysia. The therapies will be provided by Guangdong Cell Biotech in China.
This strategic move aligns with EUDA's mission to expand access to holistic healthcare solutions in Southeast Asia while diversifying its business and revenue streams. The partnership leverages Guangdong Cell Biotech's expertise in stem cell therapies and regenerative medicine for various disorders.
Positive
- New revenue stream through distribution of stem cell therapies
- Strategic expansion into regenerative medicine market
- Access to established stem cell therapy products without R&D investment
Negative
- Changed from joint venture to distribution model, potentially limiting profit potential
- Dependent on third-party distributor (Keylock) rather than direct partnership with Guangdong Cell Biotech
News Market Reaction – EUDA
On the day this news was published, EUDA declined 4.62%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerative medicine in China. It develops autologous cell treatments and tailored medicines for various disorders.
Instead of the initially contemplated joint venture, the parties have adopted a commercial distribution arrangement structure that better aligns with their respective operational models and regional market dynamics.
On April 22, 2025, CK Health Plus Sdn Bhd (“CK Health”), a wholly-owned subsidiary of EUDA and a direct seller of holistic wellness consumer products, signed a collaboration agreement with Guangdong Key Lock Health Management Co., Ltd. (“Keylock”), an authorized distributor of Guangdong Cell Biotech. Pursuant to this collaboration agreement, CK Health will market and sell to EUDA customers in Singapore and Malaysia stem cell therapies provided by Guangdong Cell Biotech in China.
This revised structure builds upon the original strategic intent of the parties to collaborate, giving EUDA access to Guangdong Cell Biotech’s cutting-edge stem cell therapies and regenerative medicine.
"This commercial distribution structure showcases our strategy to diversify our business and revenue streams," said Mr. Alfred Lim, CEO of EUDA. "Combining our mission to expand access to holistic healthcare solutions in Southeast Asia with Guangdong Cell Biotech's established stem cell therapies, we aim to transform the health and wellness landscape in the region."
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia. Our mission is to transform the health and wellness landscape by leveraging cutting-edge technology to enhance non-invasive treatments and expand holistic healthcare access in Southeast Asia. We offer a diverse portfolio of innovative non-invasive wellness products and services, including bioenergy capsules and stem cell therapies, marketed under the CK Health brand in Malaysia and Singapore.
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Guangdong Cell Biotech, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Roger Hu
+852.2232.3968
FAQ
What is the new partnership structure between EUDA and Guangdong Cell Biotech announced in April 2025?
How will EUDA stock (NASDAQ: EUDA) benefit from the Guangdong Cell Biotech distribution agreement?
What markets will EUDA's stem cell therapy distribution cover?
When did EUDA sign the collaboration agreement with Keylock for stem cell therapy distribution?
